5-[(2E)-3-(2-呋喃基)-2-丙烯-1-亚基]-2-硫代二氢-4,6(1H,5H)-嘧啶二酮 | 99974-02-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-[(2E)-3-(2-呋喃基)-2-丙烯-1-亚基]-2-硫代二氢-4,6(1H,5H)-嘧啶二酮
• 英文名称: 5-(3-furan-2-yl-allylidene)-2-thioxodihydropyrimidine-4,6-dione
• 英文别名: 5-(3t-[2]furyl-allylidene)-2-thio-barbituric acid；5-(3t-[2]Furyl-allyliden)-2-thio-barbitursaeure；5-[(E)-3-(furan-2-yl)prop-2-enylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione
• CAS: 99974-02-4
• 化学式: C₁₁H₈N₂O₃S
• 分子量: 248.262
• InChiKey: FZPZMDRQJKKBQQ-HNQUOIGGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为产物：
  描述：

  4,6-二羟基-2-巯基嘧啶 、 反-3-(2-呋喃基)丙烯醛 生成 5-[(2E)-3-(2-呋喃基)-2-丙烯-1-亚基]-2-硫代二氢-4,6(1H,5H)-嘧啶二酮
  参考文献：
  名称：

  Ponomarew; Ditschkowa, Uchenye Zapiski Saratovskogo Gosudarstvennogo Universiteta, 1955, vol. 42, p. 45,48

  摘要：

  DOI：

文献信息

• COMPOUNDS FOR USE IN CANCER THERAPY
  申请人：Connor James R.

  公开号：US20150065531A1

  公开（公告）日：2015-03-05

  Provided are methods and compositions for use in therapy, and in particular for treating cancer, preferably drug-resistant cancer, and/or radiation resistant cancer. The compounds may be used for reducing tumor size in a mammalian subject and for inducing apoptosis in a tumor cell. The methods are effective on tumor cells that are resistant to drugs such as temozolomide, doxorubicin, and geldanamycin, as well as non-resistant tumor cells. Further provided are barbiturate and thiobarbiturates diene compounds for use in treating cancer, and uses, methods and compositions relating to these compounds.

  提供了用于治疗疾病的方法和成分，特别是用于治疗癌症，优选为耐药性癌症和/或放射线耐药性癌症。这些化合物可用于减小哺乳动物主体的肿瘤大小，并诱导肿瘤细胞凋亡。这些方法对于耐药性药物如替莫唑胺、多柔比星和格尔达纳霉素以及非耐药性肿瘤细胞都有效。此外，还提供了用于治疗癌症的巴比妥和硫代巴比妥二烯化合物，以及与这些化合物相关的用途、方法和组合物。
• Design and synthesis of novel thiobarbituric acid derivatives targeting both wild-type and BRAF-mutated melanoma cells
  作者：Srinivasa Rao Ramisetti、Manoj K. Pandey、Sang Y. Lee、Deepkamal Karelia、Satya Narayan、Shantu Amin、Arun K. Sharma

  DOI：10.1016/j.ejmech.2017.11.006

  日期：2018.1

  A series of novel thio-and seleno-barbituric acid derivatives were synthesized by varying the substituents at N1 and N3 (ethyl, methyl, allyl, and phenyl), and C5 tethered with dienyl and trienyl moieties attached to substituents such as phenyl, 2-furanyl, 2-thiophenyl, l-naphthyl, and 3-pyridyl. The cytotoxic potential of these derivatives was evaluated by using MTT assay against melanoma cell lines expressing either wild-type (CHL-1) or mutant (UACC 903) BRAF gene. Among all, 2b and 8b were identified as the most potent compounds. Both 2b and 8b inhibited viability of various melanoma cells and induced cell death as evidenced by Live and Dead assay. Western blot analysis showed that they induce PARP cleavage and inhibit anti-apoptotic Bcl-2, Bcl-xL and Survivin in a dose-dependent manner within 24 h of the treatment. Novel thiobarbituric acid analogs also inhibited viability of various other solid tumor cell lines, such as pancreatic, breast, and colon. Overall, 2b, 2d, and 8b emerged as the most effective compounds and make good leads for the development of future therapeutic agents. (C) 2017 Elsevier Masson SAS. All rights reserved.
• Inhibitors of MALT1-proteolytic activity and uses thereof
  申请人：VIB VZW

  公开号：EP2222326B1

  公开（公告）日：2012-04-18
• INHIBITORS OF MALT1 PROTEOLYTIC ACTIVITY AND USES THEREOF
  申请人：VIB VZW

  公开号：EP2222326B2

  公开（公告）日：2015-02-25
• BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY
  申请人：NUHOPE, LLC

  公开号：US20180134691A1

  公开（公告）日：2018-05-17

  Provided are methods and compositions for use in therapy, and in particular for treating cancer, preferably drug-resistant cancer, and/or radiation resistant cancer. The compounds may be used for reducing tumor size in a mammalian subject and for inducing apoptosis in a tumor cell. The methods are effective on tumor cells that are resistant to drugs such as temozolomide, doxorubicin, and geldanamycin, as well as non-resistant tumor cells. Further provided are barbiturate and thiobarbiturates diene compounds for use in treating cancer, and uses, methods and compositions relating to these compounds.